Literature DB >> 34551230

Perspectives on the Treatment of Malignant Pleural Mesothelioma.

Sam M Janes1, Doraid Alrifai1, Dean A Fennell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34551230     DOI： 10.1056/NEJMra1912719

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.

Authors:  Nirosha D Perera; Aaron S Mansfield
Journal:  Curr Oncol Rep       Date:  2022-06-03       Impact factor: 5.075

Review 2.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

Review 3.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

4.  Activation of Tumor-Cell STING Primes NK-Cell Therapy.

Authors:  Elena V Ivanova; Mubin Tarannum; Marco Campisi; Erik H Knelson; Patrick H Lizotte; Matthew A Booker; Ismail Ozgenc; Moataz Noureddine; Brittany Meisenheimer; Minyue Chen; Brandon Piel; Nathaniel Spicer; Bonje Obua; Cameron M Messier; Erin Shannon; Navin R Mahadevan; Tetsuo Tani; Pieter J Schol; Anna M Lee-Hassett; Ari Zlota; Ha V Vo; Minh Ha; Arrien A Bertram; Saemi Han; Tran C Thai; Corinne E Gustafson; Kartika Venugopal; Timothy J Haggerty; Thomas P Albertson; Antja-Voy Hartley; Pinar O Eser; Ze-Hua Li; Israel Cañadas; Marina Vivero; Assunta De Rienzo; William G Richards; Adnan O Abu-Yousif; Vicky A Appleman; Richard C Gregory; Alexander Parent; Neil Lineberry; Eric L Smith; Pasi A Jänne; Juan J Miret; Michael Y Tolstorukov; Rizwan Romee; Cloud P Paweletz; Raphael Bueno; David A Barbie
Journal:  Cancer Immunol Res       Date:  2022-08-03       Impact factor: 12.020

5.  Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma.

Authors:  Hely Ollila; Mikko I Mäyränpää; Lassi Paavolainen; Juuso Paajanen; Katja Välimäki; Eva Sutinen; Henrik Wolff; Jari Räsänen; Olli Kallioniemi; Marjukka Myllärniemi; Ilkka Ilonen; Teijo Pellinen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

6.  HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.

Authors:  Clotilde Hoyos; Alexis Fontaine; Jean-Rock Jacques; Vincent Heinen; Renaud Louis; Bernard Duysinx; Arnaud Scherpereel; Eric Wasielewski; Majeed Jamakhani; Malik Hamaidia; Luc Willems
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

7.  Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research.

Authors:  Eline Janssens; Zoë Mol; Lore Vandermeersch; Sabrina Lagniau; Karim Y Vermaelen; Jan P van Meerbeeck; Christophe Walgraeve; Elly Marcq; Kevin Lamote
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

Review 8.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

9.  Molecular Radiotherapy with 177Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro.

Authors:  Tao Huang; Jae Sam Lee; Alexander L Klibanov; Jiang He
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

Review 10.  Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.

Authors:  Sophie Rovers; Annelies Janssens; Jo Raskin; Patrick Pauwels; Jan P van Meerbeeck; Evelien Smits; Elly Marcq
Journal:  Biomedicines       Date:  2022-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.